Vical Incorporated engages in the research and development of biopharmaceutical products for the prevention and treatment of serious or life-threatening diseases in the United States. The company, through its licensees and collaborators, develops a range of DNA-based vaccines and therapeutics for the prevention or treatment of infectious diseases, cardiovascular diseases, and cancer using its patented DNA delivery technologies. Its products include cytomegalovirus vaccine, which is in phase 2 clinical trials, for hematopoietic cell transplant patients; a vaccine against influenza, which is in preclinical stages; Allovectin-7, which is a plasmid/lipid complex containing the DNA sequences...